




Searching News Database: Sutent
HSMN NewsFeed - 3 Apr 2018
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
Oncternal Therapeutics Further Strengthens Leadership with Additions to Board of Directors
HSMN NewsFeed - 30 Nov 2017
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
HSMN NewsFeed - 14 Dec 2016
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
Harpoon Therapeutics Appoints Gerald McMahon, Ph.D., as President and CEO
HSMN NewsFeed - 28 Jan 2013
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
Results from Active Biotech's Phase II/III ANYARA trial for the treatment of renal cell cancer
HSMN NewsFeed - 13 Dec 2012
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 23 Apr 2012
Kolltan Pharmaceuticals Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer
Kolltan Pharmaceuticals Appoints Gerald McMahon, Ph.D., President & Chief Executive Officer
HSMN NewsFeed - 11 Oct 2011
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
Cleave Biosciences Raises $42 Million in Series A Financing for Novel Cancer Therapies
HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
HSMN NewsFeed - 18 Nov 2009
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
Asuragen Signs Development and Worldwide Distribution Agreement with Life Technologies
HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
HSMN NewsFeed - 13 May 2009
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
Follica Appoints Drug Development and Dermatology Veteran, William D. Ju, as Chief Executive Officer
HSMN NewsFeed - 26 Jan 2009
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company
HSMN NewsFeed - 21 May 2008
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
HSMN NewsFeed - 21 Apr 2008
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT
HSMN NewsFeed - 13 Sep 2007
Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
HSMN NewsFeed - 6 Aug 2007
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009
HSMN NewsFeed - 23 Jul 2007
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 21 Jun 2007
Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review
HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
HSMN NewsFeed - 20 May 2007
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
Pfizer Says Research and Development Head John LaMattina Will Retire This Year
HSMN NewsFeed - 13 Feb 2007
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
HSMN NewsFeed - 8 Feb 2007
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
HSMN NewsFeed - 14 Dec 2006
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
New Data On Pfizer's Aromasin and Ellence to Be Presented at San Antonio Breast Cancer Symposium
HSMN NewsFeed - 27 Oct 2006
S*BIO Appoints Joy Zhu Senior Vice President of Global Clinical Development
S*BIO Appoints Joy Zhu Senior Vice President of Global Clinical Development
HSMN NewsFeed - 11 Jul 2006
James L. Freddo, M.D., Joins Anadys Pharmaceuticals as Chief Medical Officer
James L. Freddo, M.D., Joins Anadys Pharmaceuticals as Chief Medical Officer
HSMN NewsFeed - 11 May 2006
Pfizer's Smoking Cessation Medicine Chantix(TM) (Varenicline) Receives FDA Approval
Pfizer's Smoking Cessation Medicine Chantix(TM) (Varenicline) Receives FDA Approval
Additional items found! 9

Members Archive contains
9 additional stories matching:
Sutent
(Password required)
Sutent
(Password required)